Business Context and Reporting Period
This Form 8-K filing by Lucid Diagnostics Inc. (LUCD) reports on events occurring on January 17, 2022. The company is an emerging growth company incorporated in Delaware, with principal executive offices in New York. The filing primarily addresses the execution of new employment agreements with key executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and employment terms rather than financial performance results.
Material Changes
The material change reported is the formalization of employment terms for the Company's Chairman, CEO, and CFO. Key terms include:
- Dr. Lishan Aklog (Chairman & CEO):
- Annual base salary: $300,000.
- Annual performance bonus: Up to 100% of base salary.
- Restricted Stock Award: 60,000 shares vesting in a single installment after three years.
- Term: Expires March 15, 2025, with automatic one-year renewals.
- Dennis M. McGrath (CFO):
- Annual base salary: $225,000.
- Annual performance bonus: Up to 70% of base salary.
- Restricted Stock Award: 60,000 shares vesting in a single installment after three years.
- Term: Expires March 15, 2025, with automatic one-year renewals.
Outlook, Risks, and Contingencies
The filing details significant severance contingencies and restrictive covenants:
- Severance Provisions: In the event of termination without cause or resignation for "good reason," executives are entitled to 12 months of base salary (or 24 months if within 60 days of a change of control), a pro rata target bonus, and 12 months of health insurance.
- Termination Notice: The Company must provide 60 days' notice for termination without cause (180 days for Dr. Aklog during the initial term). Executives must provide 30 days' notice for resignation without good reason.
- Non-Compete: Executives are restricted from competing with the Company for one year post-employment (two years in the event of a change of control).
- Parent Company Exception: The agreements explicitly allow executives to serve as officers and directors of PAVmed Inc., the Company's parent.
Investor Verification Checklist
- Verify the full text of the Employment Agreements (Exhibits 10.1 and 10.2) for specific definitions of "cause," "good reason," and "change of control."
- Confirm the impact of the 120,000 total restricted stock awards on future dilution and the specific vesting acceleration clauses.
- Review the Company's cash position to assess the ability to fund potential severance obligations (up to 24 months of salary plus bonuses) in a change of control scenario.
- Check for any subsequent filings regarding the performance objectives required to trigger the annual bonuses.